(INDV) Indivior Ordinary Shares - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: GB00BN4HT335
Stock: Buprenorphine, Sublingual, Injection, Naloxone, Overdose
Total Rating 74
Risk 69
Buy Signal -0.24
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 51.3% |
| Relative Tail Risk | -18.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.52 |
| Alpha | 200.11 |
| Character TTM | |
|---|---|
| Beta | 0.657 |
| Beta Downside | 0.596 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.89% |
| CAGR/Max DD | 0.18 |
Description: INDV Indivior Ordinary Shares January 13, 2026
Indivior PLC (NASDAQ: INDV) develops, manufactures, and markets buprenorphine-based therapies for opioid dependence across the U.S., Europe, Canada, Australia, and other regions, with its flagship products including SUBLOCADE monthly injections, SUBOXONE Film and Tablet (buprenorphine/naloxone), SUBUTEX Tablet, and the opioid-overdose reversal spray OPVEE.
The pipeline features INDV-2000, a selective orexin-1 receptor antagonist in Phase 2 for moderate-to-severe OUD, and INDV-6001, a long-acting buprenorphine injectable co-developed with Alar Pharmaceuticals, indicating a strategic focus on next-generation, longer-duration treatments.
Key industry drivers include the U.S. opioid-use-disorder market, projected to exceed $12 billion by 2027, and rising reimbursement pressure from Medicaid and private insurers, which together shape revenue growth; Indivior reported FY 2023 revenue of $1.2 billion, a 9 % YoY increase, while its SUBLOCADE sales grew 22 % driven by expanded formulary access.
For a deeper data-driven assessment, consider exploring ValueRay’s analyst tools to evaluate INDV’s valuation metrics and competitive positioning.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 166.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 27.09 > 1.0 |
| NWC/Revenue: -3.64% < 20% (prev -13.78%; Δ 10.14% < -1%) |
| CFO/TA 0.14 > 3% & CFO 193.4m > Net Income 166.0m |
| Net Debt (-89.0m) to EBITDA (315.0m): -0.28 < 3 |
| Current Ratio: 0.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (129.0m) vs 12m ago -3.41% < -2% |
| Gross Margin: 82.81% > 18% (prev 0.80%; Δ 8201 % > 0.5%) |
| Asset Turnover: 82.01% > 50% (prev 80.81%; Δ 1.21% > 0%) |
| Interest Coverage Ratio: 5.73 > 6 (EBITDA TTM 315.0m / Interest Expense TTM 52.0m) |
Altman Z'' 0.19
| A: -0.03 (Total Current Assets 922.0m - Total Current Liabilities 965.0m) / Total Assets 1.42b |
| B: -0.24 (Retained Earnings -346.0m / Total Assets 1.42b) |
| C: 0.21 (EBIT TTM 298.0m / Avg Total Assets 1.44b) |
| D: -0.19 (Book Value of Equity -316.0m / Total Liabilities 1.62b) |
| Altman-Z'' Score: 0.19 = B |
Beneish M -3.22
| DSRI: 1.09 (Receivables 272.0m/251.0m, Revenue 1.18b/1.18b) |
| GMI: 0.97 (GM 82.81% / 79.97%) |
| AQI: 0.64 (AQ_t 0.24 / AQ_t-1 0.38) |
| SGI: 1.00 (Revenue 1.18b / 1.18b) |
| TATA: -0.02 (NI 166.0m - CFO 193.4m) / TA 1.42b) |
| Beneish M-Score: -3.22 (Cap -4..+1) = AA |
What is the price of INDV shares?
As of February 08, 2026, the stock is trading at USD 34.36 with a total of 1,502,971 shares traded.
Over the past week, the price has changed by -2.88%, over one month by -5.06%, over three months by +7.81% and over the past year by +222.63%.
Over the past week, the price has changed by -2.88%, over one month by -5.06%, over three months by +7.81% and over the past year by +222.63%.
Is INDV a buy, sell or hold?
Indivior Ordinary Shares has received a consensus analysts rating of 4.71.
Therefore, it is recommended to buy INDV.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the INDV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 45.6 | 32.6% |
| Analysts Target Price | 45.6 | 32.6% |
| ValueRay Target Price | 38.5 | 12% |
INDV Fundamental Data Overview February 01, 2026
P/E Trailing = 35.38
P/E Forward = 11.2994
P/S = 3.7486
P/B = 145.2492
Revenue TTM = 1.18b USD
EBIT TTM = 298.0m USD
EBITDA TTM = 315.0m USD
Long Term Debt = 304.0m USD (from longTermDebt, last quarter)
Short Term Debt = 28.0m USD (from shortTermDebt, last quarter)
Debt = 356.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -89.0m USD (from netDebt column, last quarter)
Enterprise Value = 4.33b USD (4.42b + Debt 356.0m - CCE 445.0m)
Interest Coverage Ratio = 5.73 (Ebit TTM 298.0m / Interest Expense TTM 52.0m)
EV/FCF = 32.23x (Enterprise Value 4.33b / FCF TTM 134.5m)
FCF Yield = 3.10% (FCF TTM 134.5m / Enterprise Value 4.33b)
FCF Margin = 11.39% (FCF TTM 134.5m / Revenue TTM 1.18b)
Net Margin = 14.06% (Net Income TTM 166.0m / Revenue TTM 1.18b)
Gross Margin = 82.81% ((Revenue TTM 1.18b - Cost of Revenue TTM 203.0m) / Revenue TTM)
Gross Margin QoQ = 73.25% (prev 82.78%)
Tobins Q-Ratio = 3.06 (Enterprise Value 4.33b / Total Assets 1.42b)
Interest Expense / Debt = 3.37% (Interest Expense 12.0m / Debt 356.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = 235.4m (EBIT 298.0m * (1 - 21.00%))
Current Ratio = 0.96 (Total Current Assets 922.0m / Total Current Liabilities 965.0m)
Debt / Equity = -1.72 (negative equity) (Debt 356.0m / totalStockholderEquity, last quarter -207.0m)
Debt / EBITDA = -0.28 (Net Debt -89.0m / EBITDA 315.0m)
Debt / FCF = -0.66 (Net Debt -89.0m / FCF TTM 134.5m)
Total Stockholder Equity = -274.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.53% (Net Income 166.0m / Total Assets 1.42b)
RoE = -60.42% (negative equity) (Net Income TTM 166.0m / Total Stockholder Equity -274.8m)
RoCE = 1019 % (out of range, set to none) (EBIT 298.0m / Capital Employed (Equity -274.8m + L.T.Debt 304.0m))
RoIC = 446.3% (NOPAT 235.4m / Invested Capital 52.8m)
WACC = 7.92% (E(4.42b)/V(4.78b) * Re(8.34%) + D(356.0m)/V(4.78b) * Rd(3.37%) * (1-Tc(0.21)))
Discount Rate = 8.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.18%
[DCF Debug] Terminal Value 70.61% ; FCFF base≈134.5m ; Y1≈88.3m ; Y5≈40.3m
Fair Price DCF = 7.11 (EV 799.4m - Net Debt -89.0m = Equity 888.4m / Shares 125.0m; r=7.92% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 18.92 | EPS CAGR: -4.73% | SUE: -0.86 | # QB: 0
Revenue Correlation: 89.56 | Revenue CAGR: 9.56% | SUE: 2.25 | # QB: 4
EPS next Quarter (2026-03-31): EPS=0.65 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=5
EPS next Year (2026-12-31): EPS=2.99 | Chg30d=+0.096 | Revisions Net=+3 | Growth EPS=+28.1% | Growth Revenue=-3.9%
P/E Forward = 11.2994
P/S = 3.7486
P/B = 145.2492
Revenue TTM = 1.18b USD
EBIT TTM = 298.0m USD
EBITDA TTM = 315.0m USD
Long Term Debt = 304.0m USD (from longTermDebt, last quarter)
Short Term Debt = 28.0m USD (from shortTermDebt, last quarter)
Debt = 356.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -89.0m USD (from netDebt column, last quarter)
Enterprise Value = 4.33b USD (4.42b + Debt 356.0m - CCE 445.0m)
Interest Coverage Ratio = 5.73 (Ebit TTM 298.0m / Interest Expense TTM 52.0m)
EV/FCF = 32.23x (Enterprise Value 4.33b / FCF TTM 134.5m)
FCF Yield = 3.10% (FCF TTM 134.5m / Enterprise Value 4.33b)
FCF Margin = 11.39% (FCF TTM 134.5m / Revenue TTM 1.18b)
Net Margin = 14.06% (Net Income TTM 166.0m / Revenue TTM 1.18b)
Gross Margin = 82.81% ((Revenue TTM 1.18b - Cost of Revenue TTM 203.0m) / Revenue TTM)
Gross Margin QoQ = 73.25% (prev 82.78%)
Tobins Q-Ratio = 3.06 (Enterprise Value 4.33b / Total Assets 1.42b)
Interest Expense / Debt = 3.37% (Interest Expense 12.0m / Debt 356.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = 235.4m (EBIT 298.0m * (1 - 21.00%))
Current Ratio = 0.96 (Total Current Assets 922.0m / Total Current Liabilities 965.0m)
Debt / Equity = -1.72 (negative equity) (Debt 356.0m / totalStockholderEquity, last quarter -207.0m)
Debt / EBITDA = -0.28 (Net Debt -89.0m / EBITDA 315.0m)
Debt / FCF = -0.66 (Net Debt -89.0m / FCF TTM 134.5m)
Total Stockholder Equity = -274.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.53% (Net Income 166.0m / Total Assets 1.42b)
RoE = -60.42% (negative equity) (Net Income TTM 166.0m / Total Stockholder Equity -274.8m)
RoCE = 1019 % (out of range, set to none) (EBIT 298.0m / Capital Employed (Equity -274.8m + L.T.Debt 304.0m))
RoIC = 446.3% (NOPAT 235.4m / Invested Capital 52.8m)
WACC = 7.92% (E(4.42b)/V(4.78b) * Re(8.34%) + D(356.0m)/V(4.78b) * Rd(3.37%) * (1-Tc(0.21)))
Discount Rate = 8.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.18%
[DCF Debug] Terminal Value 70.61% ; FCFF base≈134.5m ; Y1≈88.3m ; Y5≈40.3m
Fair Price DCF = 7.11 (EV 799.4m - Net Debt -89.0m = Equity 888.4m / Shares 125.0m; r=7.92% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 18.92 | EPS CAGR: -4.73% | SUE: -0.86 | # QB: 0
Revenue Correlation: 89.56 | Revenue CAGR: 9.56% | SUE: 2.25 | # QB: 4
EPS next Quarter (2026-03-31): EPS=0.65 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=5
EPS next Year (2026-12-31): EPS=2.99 | Chg30d=+0.096 | Revisions Net=+3 | Growth EPS=+28.1% | Growth Revenue=-3.9%